Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Majalah Farmaseutik JSFK (Jurnal Sains Farmasi & Klinis)
Molidia, Sri Rahmat
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Comparison of Clinical Outcomes Between Acetylcysteine and Ambroxol in Post Acute Exacerbation of COPD Patients Molidia, Sri Rahmat; Pramantara, Dewa Putu; Ikawati, Zullies
JSFK (Jurnal Sains Farmasi & Klinis) Vol 11 No 1 (2024): J Sains Farm Klin 11(1), April 2024
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.11.1.58-66.2024

Abstract

Literature studies show that the use of acetylcysteine or ambroxol can accelerate improvement of clinical outcomes of post acute exacerbation chronic obstructive pulmonary disease (AECOPD) patients. This study aims to compare the clinical outcomes of acetylcysteine and ambroxol administration in post AECOPD patients. The study was cohort design, prospective, to comparison of clinical outcomes of acetylcysteine and ambroxol with post AECOPD outpatients coming for clinical chekups in August 2023 at Respira Lung Hospital Yogyakarta. Clinical outcomes parameters were observed on day zero and thirty for CAT score and day zero and four for cough score. The patients were categorized into two groups: acetylcysteine group (n=30) and ambroxol group (n=30). There was no significant difference between two groups to change of CAT score and cough score (p>0.05) post AECOPD. The acetylcysteine group compared to ambroxol, there was a mean decrease in morning cough score -1.10±1.11 vs -0.87±1.12 (p=0.228), night cough score -1.53±1.43 vs -1.13±1.31 (p=0.438), and CAT score -2.43±5.45 vs -2.90±3.41 (p=0.391). Providing additional therapy of acetylcysteine or ambroxol in this study did not significantly reduce cough scores and CAT scores in post AECOPD patients.
Kajian Literatur: Efektivitas Asetilsistein Dosis Tinggi Pada Pasien PPOK Molidia, Sri Rahmat; Pramantara, Dewa Putu; Ikawati, Zullies
Majalah Farmaseutik Vol 21, No 3 (2025)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v21i3.93852

Abstract

Penyakit paru obstruktif kronik (PPOK) merupakan penyebab utama mortalitas dan morbiditas di seluruh dunia, ditandai dengan keterbatasan aliran udara yang persisten, hipersekresi mukus, stres oksidatif, dan inflamasi saluran napas. Asetilsistein memiliki sifat antioksidan dan antiinflamasi, yang telah menunjukkan manfaat bergantung pada dosisnya. Review ini menilai efektivitas dosis tinggi dari asetilsisitein pada pasien PPOK dalam memperbaiki luaran klinis dan frekuensi eksaserbasi. Studi Randomized Control Trial (RCT) dilibatkan dalam kajian literatur ini mengikuti daftar checklist PRISMA. Hasil review dari 6 RCT menunjukkan bahwa pemberian asetilsistein dosis tinggi (>400 mg perhari) secara signifikan dapat menurunkan frekuensi eksaserbasi, memperbaiki fungsi paru (FEV1, FVC, FEV/FVC), perubahan biomarker oksidasi dan inflamasi (Malondialdehid, Glutation, Glutation Peroksida, Cystein, C-Reactive protein). Kesimpulan dari penambahan terapi asetilsistein dosis tinggi mampu menurunkan frekuensi eksaserbasi dan perbaikan klinis secara signifikan dibandingkan plasebo
Co-Authors Pramantara, Dewa Putu